EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eterna Therapeutics's enterprise value is $45.85 Mil.
Eterna Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.40 Mil. Therefore, Eterna Therapeutics's EV-to-EBITDA for today is -2.36.
The historical rank and industry rank for Eterna Therapeutics's EV-to-EBITDA or its related term are showing as below:
ERNA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.53 Med: -2.31 Max: -2.16
Current: -2.36
During the past 4 years, the highest EV-to-EBITDA of Eterna Therapeutics was -2.16. The lowest was -2.53. And the median was -2.31.
ERNA's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs ERNA: -2.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Eterna Therapeutics's stock price is $1.96.
Eterna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.080. Therefore, Eterna Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Eterna Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Eterna Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eterna Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eterna Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eterna Therapeutics's EV-to-EBITDA falls into.
Eterna Therapeutics EV-to-EBITDA Calculation
Eterna Therapeutics's EV-to-EBITDA for today is calculated as:
Eterna Therapeutics's current Enterprise Value is $45.85 Mil.
Eterna Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Eterna Therapeutics's PE Ratio for today is calculated as:
Eterna Therapeutics's share price for today is $1.96.
Eterna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Eterna Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Eterna Therapeutics (Eterna Therapeutics) Business Description
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERNA has been successfully added to your 